as 12-18-2024 3:30pm EST
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The Company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
Founded: | 2008 | Country: | United States |
Employees: | N/A | City: | BROOMFIELD |
Market Cap: | 1.7M | IPO Year: | 2022 |
Target Price: | $1.30 | AVG Volume (30 days): | 991.9K |
Analyst Decision: | Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.06 | EPS Growth: | N/A |
52 Week Low/High: | $0.10 - $7.39 | Next Earning Date: | 11-14-2024 |
Revenue: | $49,289 | Revenue Growth: | -41.41% |
Revenue Growth (this year): | -25.6% | Revenue Growth (next year): | 186.36% |
ACON Breaking Stock News: Dive into ACON Ticker-Specific Updates for Smart Investing
Zacks
10 hours ago
ACCESSWIRE
15 days ago
GlobeNewswire
a month ago
ACCESSWIRE
a month ago
GlobeNewswire
2 months ago
GlobeNewswire
3 months ago
MT Newswires
3 months ago
GlobeNewswire
3 months ago
The information presented on this page, "ACON Aclarion Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.